Aandelen in “Productie van biologische producten”

Aandeel Datum Koers Evolutie
vlag Outlook Therapeutics Inc 14/04 0,253 USD
-0,55% 		-0,55%

Nieuws over “Productie van biologische producten”

14/04 · Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR · Persbericht

14/04 · Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR · Persbericht

14/04 · Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results · Persbericht

13/04 · Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform · Persbericht

13/04 · Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer · Persbericht

10/04 · Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

10/04 · RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 · Persbericht

10/04 · ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 · Persbericht

9/04 · Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA · Persbericht

7/04 · Monthly information on share capital and company voting rights · Persbericht

7/04 · GENFIT Announces Publication of the 2025 Universal Registration Document   · Persbericht

7/04 · Belgen cashen 125 miljoen dollar op miljardenovername van Duits biotechbedrijf · Tijd.be (€)

Het Belgische biotechfonds Fund+ strijkt als vroege investeerder minstens 125 miljoen dollar op bij de verkoop van het Duitse biotechbedrijf Tubulis aan de Amerikaanse farmareus Gilead.

7/04 · Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology · Persbericht

6/04 · Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners · Persbericht

6/04 · AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE · Persbericht

6/04 · Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio · Persbericht

3/04 · REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights · Persbericht

3/04 · ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 · Persbericht

2/04 · Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 · Persbericht

2/04 · GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update   · Persbericht

2/04 · Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA · Persbericht

Mijn selecties